Overview Selumetinib Paediatric NF1 Japan Study Status: Active, not recruiting Trial end date: 2022-09-09 Target enrollment: Participant gender: Summary This is a phase I open label study designed to evaluate the safety, tolerability, PK and efficacy of selumetinib in Japanese paediatric patients with neurofibromatosis type 1 and inoperable and symptomatic plexiform neurofibroma. Phase: Phase 1 Details Lead Sponsor: AstraZeneca